Palbociclib US FDA Label

  • Compound: 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
  • Description: Palbociclib is a member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combination with letrozole for the treatment of metastatic breast cancer. It has a role as an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor and an antineoplastic agent. It is a pyridopyrimidine, an aminopyridine, a secondary amino compound, a member of piperidines, an aromatic ketone, a member of cyclopentanes and a tertiary amino compound.

Identifiers (4)

  • International Nonproprietary Name: PALBOCICLIB [INN] (Source: PubChem)
  • KEGG Drug ID: D10372 (Source: PubChem)
  • USFDA Precision ID: UNII-G9ZF61LE7G (Source: PubChem)
  • United States Adopted Name: Palbociclib [USAN] (Source: PubChem)